Skip to main content

Erratum to: Decline in breast cancer incidence due to removal of promoter: combination estrogen plus progestin

Due to an oversight, the author of the above article [1] was incorrectly listed as having no competing interests. The competing interests section of this article should have read:

References

  1. 1.

    Colditz GA: Decline in breast cancer incidence due to removal of promoter: combination estrogen plus progestin. Breast Cancer Research. 2007, 9: 108-10.1186/bcr1736.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Graham A Colditz.

Additional information

Competing interests

GC has served as an expert witness for plaintiff lawyers preparing hormone therapy litigation. GC has received research support from GlaxoSmithKline, from the American Cancer Society, and from the Breast Cancer Research Foundation. No group or organization funded this manuscript.

The online version of the original article can be found at 10.1186/bcr1736

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Colditz, G.A. Erratum to: Decline in breast cancer incidence due to removal of promoter: combination estrogen plus progestin. Breast Cancer Res 9, 401 (2007). https://doi.org/10.1186/bcr1786

Download citation